Sang Ho Jang agreed to acquire unknown minority stake in Bioceltran Co., Ltd from Quest PharmaTech Inc. (TSXV:QPT) for CAD 0.3 million on September 28, 2022. Quest PharmaTech will receive an upfront payment of CAD 0.09 million upon agreement execution and a second and final payment of CAD 0.21 million within 12 months. As part of the transaction, the PDT technology license agreement with Bioceltran for the SL017 and SL052 technologies will be terminated so that Quest has full control on the future development of the technology.

Sang Ho Jang completed the acquisition of unknown minority stake in Bioceltran Co., Ltd from Quest PharmaTech Inc. (TSXV:QPT) on September 28, 2022.